Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II StudyQing Wei, Jieer Ying, Weijun Chen et al.|The Oncologist|2024Cited by 10
Biliary Tract Cancer in Eastern China: A Multicenter Retrospective AnalysisYiwen Zhou, Jieer Ying, Haimin Weng et al.|SSRN Electronic Journal|2025Cited by 0